On Tuesday, Deutsche Bank raised its rating on shares of BrightSpring Health (NASDAQ:BTSG) from Hold to Buy, maintaining a price target of $11.50. The upgrade comes as the healthcare services provider's stock has experienced a significant decline since its initial public offering (IPO). BrightSpring Health's shares have fallen approximately 28% from their $13 IPO price after the pricing on January 25, 2024.
The firm initially issued a Hold rating for BrightSpring Health on February 20, 2024, with the same price target of $11.50, based on an 8x 2025E EBITDA multiple. Since that time, the stock has decreased by 14%. Despite the recent drop in share price, the fundamental outlook for the company remains unchanged, and the current target price suggests around a 24% upside from the stock's present level.
Deutsche Bank's decision to upgrade the stock occurs ahead of BrightSpring Health's first earnings release as a public company, scheduled for Thursday. The firm has not altered any of its estimates ahead of the earnings report and continues to project a 2024 EBITDA of $557 million.
This forecast represents a 5% year-over-year growth based on their 2023 forecast. The projection does not account for future mergers and acquisitions (M&A), although the firm anticipates the possibility of a 1-2% additional upside from such activities.
The analyst's expectations align with BrightSpring Health's initial guidance for 2024, which is expected to be shared alongside the fourth-quarter earnings. The firm's anticipation of the company's performance includes the potential for growth through acquisitions, which could provide additional value beyond the current guidance framework.
InvestingPro Insights
Amidst the recent volatility in BrightSpring Health's (NASDAQ:BTSG) stock price, InvestingPro data sheds light on some key financial metrics that may be influencing investor sentiment. The company's market capitalization stands at $1.59 billion, reflecting the market's current valuation of the business. Despite a challenging period, with the stock taking a significant hit over the past week, declining by 11.22%, and faring poorly over the last month with a 15.82% drop, analysts remain optimistic about BrightSpring Health's future profitability.
One of the InvestingPro Tips highlights that BrightSpring Health operates with a significant debt burden, which is an important factor for investors to consider, especially when the company is trading near its 52-week low. The stock's price to earnings (P/E) ratio, at -6.51, and an adjusted P/E ratio for the last twelve months as of Q3 2023 at -8.48, underline the company's current lack of profitability. However, with a revenue growth of 11.53% during the same period, there are signs of underlying business growth.
Furthermore, analysts predict that the company will be profitable this year, which could be a turning point for the stock. This aligns with Deutsche Bank's positive stance and their maintained price target of $11.50, suggesting a potential upside from the current price level. Notably, BrightSpring Health does not pay a dividend, which may influence the investment decisions of income-focused shareholders.
For investors looking for a comprehensive analysis, there are additional InvestingPro Tips available on BrightSpring Health, which could provide deeper insights into the company's financial health and future prospects. To explore these tips and benefit from the expert analysis, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.